Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Walvax Biotechnology Co., Ltd.
  6. News
  7. Summary
    300142   CNE100000WN2

WALVAX BIOTECHNOLOGY CO., LTD.

(300142)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021

08/27/2021 | 09:45am EDT

Walvax Biotechnology Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 1,349.755 million compared to CNY 573.455 million a year ago. Operating income was CNY 466.419 million compared to CNY 118.218 million a year ago. Net income was CNY 319.196 million compared to CNY 61.491 million a year ago. Basic earnings per share from continuing operations was CNY 0.2048 compared to CNY 0.04 a year ago. Diluted earnings per share from continuing operations was CNY 0.2016 compared to CNY 0.0395 a year ago.


© S&P Capital IQ 2021
All news about WALVAX BIOTECHNOLOGY CO., LTD.
10/16Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it has received CN..
CI
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/14Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it expects to rece..
CI
08/27WALVAX BIOTECHNOLOGY : Nepal allows late-stage trials for Chinese mRNA vaccine candidate -..
RE
08/27Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30..
CI
08/19WALVAX BIOTECHNOLOGY : China's mRNA vaccine technology firm Abogen raises over $700 millio..
RE
07/27Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it has received CN..
CI
06/10Jiangsu Walvax Biotechnology Co., Ltd. announced that it has received CNY 30 million in..
CI
06/10Beijing Walvax Innovation Biotechnology Co., Ltd. announced that it has received CNY 58..
CI
06/02China shares end lower on profit-booking of tech, healthcare stocks
RE
More news
Financials
Sales 2021 4 613 M 723 M 723 M
Net income 2021 1 399 M 219 M 219 M
Net Debt 2021 - - -
P/E ratio 2021 67,5x
Yield 2021 0,27%
Capitalization 94 034 M 14 728 M 14 730 M
Capi. / Sales 2021 20,4x
Capi. / Sales 2022 14,6x
Nbr of Employees 1 237
Free-Float 28,0%
Chart WALVAX BIOTECHNOLOGY CO., LTD.
Duration : Period :
Walvax Biotechnology Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WALVAX BIOTECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 60,04 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Run Sheng Jiang President & Director
Hua Zhou Chief Financial Officer
Yun Chun Li Chairman
Ling Ling Tang Chairman-Supervisory Board
Chao Hong Na Independent Director
Sector and Competitors
1st jan.Capi. (M$)
WALVAX BIOTECHNOLOGY CO., LTD.55.71%14 728
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464